Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: A national cancer institute organ dysfunction working group study

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3660-3666

  Synold, Timothy W ^a   Takimoto, Chris H ^b   Doroshow, James H ^a   Gandara, David ^c   Mani, Sridhar ^d   Remick, Scot C ^e   Mulkerin, Daniel L ^f   Hamilton, Anne ^g   Sharma, Sunil ^h   Ramanathan, Ramesh K ⁱ   Lenz, Heinz Josef ^j   Graham, Martin ^k   Longmate, Jeffrey ^a   Kaufman, Bennett M ^l   Ivy, Percy ^m  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CTRC Institute for Drug Development   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k Sanofi Synthelabo   (United States)

^l PSI International Inc   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; OXALIPLATIN; PLATINUM;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; LARYNX CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSORY NEUROPATHY; URINE; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 34250784654     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2385     Document Type: Article

References (10)

1. Mani S, Graham MA, Bregman DB, Ivy P, Chaney SG. Oxaliplatin: a review of evolving concepts. Cancer Invest 2002;20:246-63.
2. Misset JL. Oxaliplatin in practice. Br J Cancer 1998;77 Suppl 4:4-7.
3. Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastaticpa tterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986;150:195-203.
4. Food and Drug Administration. Guidance for Industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. In: Services USDoHaH, editor. 2003.
5. Egorin M. The effects of organ dysfunction on drug dosing. Clin Adv Hematol Oncol 2006;4:116-8.
6. Takimoto CH, Remick SC, Sharma S, et al. Doseescalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003;21:2664-72.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
8. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000;6:1205-18.
9. Allain P, Heudi O, Cailleux A, et al. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 2000;28:1379-84.
10. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.